We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
-1.17%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$1.54B
AUM Growth
-$101M
Cap. Flow
-$61.8M
Cap. Flow %
-4.02%
Top 10 Hldgs %
28.17%
Holding
136
New
11
Increased
33
Reduced
22
Closed
8

Top Buys

Rank Stock Value
1
INST
Instructure, Inc.
INST
+$14.4M
2
WCN
Waste Connections
WCN
+$13.3M
3
W icon
Wayfair
W
+$12.6M
4
SNA icon
Snap-on
SNA
+$11.4M
5
DOOR
MASONITE INTERNATIONAL CORP
DOOR
+$6.18M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$18.9M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$16.6M
3
LRCX icon
Lam Research
LRCX
+$16.5M
4
WAB icon
Wabtec
WAB
+$15.7M
5
PANW icon
Palo Alto Networks
PANW
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 35.01%
2 Technology 20.32%
3 Consumer Discretionary 15.87%
4 Industrials 12.46%
5 Utilities 5.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
76
Coherus Oncology
CHRS
$205M
$4.08M 0.27%
145,000
– –
INCY icon
77
Incyte
INCY
$24.7B
$4.01M 0.26%
40,000
– –
VYGR icon
78
Voyager Therapeutics
VYGR
$190M
$3.82M 0.25%
300,000
– –
ATRC icon
79
AtriCure
ATRC
$2.86B
$3.52M 0.23%
180,000
– –
BLCM
80
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$3.4M 0.22%
+25,000
New +$4.44M
RGEN icon
81
Repligen
RGEN
$9.86B
$3.39M 0.22%
110,000
– –
ALNY icon
82
Alnylam Pharmaceuticals
ALNY
$31.9B
$3.37M 0.22%
90,000
– –
LKFT
83
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$3.34M 0.22%
52,000
– –
EPZM
84
DELISTED
Epizyme, Inc
EPZM
$3.33M 0.22%
275,000
– –
HRTX icon
85
Heron Therapeutics
HRTX
$59.6M
$2.95M 0.19%
+225,000
New +$3.53M
NGNE icon
86
Neurogene
NGNE
$674M
$2.89M 0.19%
+8,750
New +$2.35M
CDTX
87
DELISTED
Cidara Therapeutics
CDTX
$2.75M 0.18%
13,200
– –
KA
88
DELISTED
Kineta, Inc. Common Stock
KA
$2.7M 0.18%
1,571
– –
AGTC
89
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.61M 0.17%
279,100
– –
NTUS
90
DELISTED
Natus Medical Inc
NTUS
$2.61M 0.17%
75,000
– –
VRTX icon
91
Vertex Pharmaceuticals
VRTX
$130B
$2.55M 0.17%
34,600
– –
TGTX icon
92
TG Therapeutics
TGTX
$8.12B
$2.5M 0.16%
537,600
– –
TTPH
93
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.42M 0.16%
30,000
– –
GBT
94
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.38M 0.16%
165,000
– –
NVAX icon
95
Novavax
NVAX
$1.52B
$1.83M 0.12%
72,485
-36,500
-33% -$1.06M
SYRS
96
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.82M 0.12%
15,000
– –
JUNO
97
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.7M 0.11%
90,000
– –
CTMX icon
98
CytomX Therapeutics
CTMX
$586M
$1.65M 0.11%
150,000
– –
SEP
99
DELISTED
Spectra Engy Parters Lp
SEP
$1.6M 0.1%
35,000
+3,000
+9% +$130K
HTGC icon
100
Hercules Capital
HTGC
$3.3B
$1.5M 0.1%
106,000
+27,000
+34% +$368K
2 3
4
5 6

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Eventide Asset Management held 136 positions worth $1.54B, down 6.2% from $1.64B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Eventide Asset Management withdrew a net $61.8M in Q4 2016, closing 8 positions and reducing 22 holdings. Its most notable exit was Ormat Technologies, an estimated $13.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Eventide Asset Management opened a new position in Instructure, Inc. worth $13.1M.

  • Eventide Asset Management's largest Q4 2016 buy was Instructure, Inc.: 670,000 shares worth $13.1M.
  • Eventide Asset Management added most to Snap-on in Q4 2016, an estimated $11.4M increase.
  • Eventide Asset Management's biggest Q4 2016 reduction was Celgene Corp, cutting an estimated $18.9M.
  • Eventide Asset Management fully exited Ormat Technologies in Q4 2016, selling an estimated $13.4M.
  • Eventide Asset Management's ten largest holdings make up 28% of its $1.54B portfolio in Q4 2016.
  • Eventide Asset Management opened 11 new positions and closed 8 in Q4 2016.
  • Eventide Asset Management's portfolio value fell 6.2% quarter-over-quarter to $1.54B.

Based on Eventide Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.